Department of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.
Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
J Neurol. 2020 Oct;267(10):2790-2796. doi: 10.1007/s00415-020-09944-8. Epub 2020 Jun 3.
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
一种新型冠状病毒（COVID-19）引发的严重急性呼吸系统综合症，引起了长期接受免疫疗法的多发性硬化症（MS）患者的健康关注。在大流行期间管理 MS 仍然具有挑战性，因为经验很少，也没有循证指南。我们介绍了 5 名接受特立氟胺治疗的 MS 患者，他们随后发生了活动性 COVID-19 感染。这些患者继续接受特立氟胺治疗，感染自行缓解，MS 无复发。这些观察结果对 COVID-19 大流行期间 MS 的管理具有重要意义。
